Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
Want to see BDTX full AI Analyst Report?
Total Valuation
Black Diamond Therapeutics has a market cap or net worth of $157.58M. The enterprise value is $145.39M.
Market Cap$157.58M
Enterprise Value$145.39M
Share Statistics
Black Diamond Therapeutics has 57,301,773 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,301,773
Owned by Insiders9.03%
Owned by Institutions34.13%
Financial Efficiency
Black Diamond Therapeutics’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 15.61%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)15.61%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee2.92M
Profits Per Employee931.96K
Employee Count24
Asset Turnover0.49
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Black Diamond Therapeutics is ―. Black Diamond Therapeutics’s PEG ratio is -0.05.
PE Ratio―
PS Ratio1.97
PB Ratio1.23
Price to Fair Value1.23
Price to FCF4.67
Price to Operating Cash Flow-4.63
PEG Ratio-0.05
Income Statement
In the last 12 months, Black Diamond Therapeutics had revenue of 70.00M and earned 22.37M in profits. Earnings per share was 0.39.
Revenue70.00M
Gross Profit69.67M
Operating Income19.87M
Pretax Income22.37M
Net Income22.37M
EBITDA20.20M
Earnings Per Share (EPS)0.39
Cash Flow
In the last 12 months, operating cash flow was -34.03M and capital expenditures 0.00, giving a free cash flow of -34.03M billion.
Operating Cash Flow-34.03M
Free Cash Flow-34.03M
Free Cash Flow per Share-0.59
Dividends & Yields
Black Diamond Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.32
52-Week Price Change30.33%
50-Day Moving Average2.33
200-Day Moving Average2.94
Relative Strength Index (RSI)75.58
Average Volume (3m)654.24K
Important Dates
Black Diamond Therapeutics upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Black Diamond Therapeutics as a current ratio of 8.42, with Debt / Equity ratio of 17.14%
Current Ratio8.42
Quick Ratio8.42
Debt to Market Cap0.00
Net Debt to EBITDA-0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Black Diamond Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Black Diamond Therapeutics EV to EBITDA ratio is 6.55, with an EV/FCF ratio of 4.47.
EV to Sales1.89
EV to EBITDA6.55
EV to Free Cash Flow4.47
EV to Operating Cash Flow4.47
Balance Sheet
Black Diamond Therapeutics has $118.26M in cash and marketable securities with $17.88M in debt, giving a net cash position of $100.38M billion.
Cash & Marketable Securities$118.26M
Total Debt$17.88M
Net Cash$100.38M
Net Cash Per Share$1.75
Tangible Book Value Per Share$1.97
Margins
Gross margin is 0.00%, with operating margin of 28.39%, and net profit margin of 31.95%.
Gross Margin0.00%
Operating Margin28.39%
Pretax Margin31.95%
Net Profit Margin31.95%
EBITDA Margin28.85%
EBIT Margin28.39%
Analyst Forecast
The average price target for Black Diamond Therapeutics is $10.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.25
Price Target Upside234.97% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-100.00%
EPS Growth Forecast-1056.82%